- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04673942
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors (BETA-PRIME)
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a dose escalation protocol to determine, first and foremost, the safety, tolerability and feasibility of intratumoral administration of AdAPT-001.
The study has 3 parts. Different groups of patients will participate in each part.
PART 1: Dose Escalation Safety Run-In (Enrollment Completed)
During PART 1, all participants will be treated with AdAPT-001 as a single injection, one time. Participants will be assigned to different dose levels to find the highest dose of AdAPT-001 that is safe and tolerable.
PART 2: Dose Expansion Single-Agent (Enrollment Completed)
All participants in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.
PART 3: Expansion
Subjects will be assigned to the following two arms. If a checkpoint inhibitor is indicated for the subject, the subject may be enrolled on Arm 2 per investigator discretion, otherwise subjects may be enrolled on Arm 1.
Arm 1: Intratumoral administration of AdAPT-001 (1.0 x 10¹² viral particles) on Day 1 and 15 of each 28-day cycle for up to 12 injections.
Arm 2: Intratumoral administration of AdAPT-001 (1.0 x 10¹² viral particles) on Day 1 and 15 of each 28-day cycle for up to 12 injections plus a checkpoint inhibitor per investigator discretion
PHASE 2:
Subjects with advanced solid tumors will participate in a basket two-arm parallel group evaluation (Phase 2) where eligible participants will be assigned to the following two arms based on confirmed histology by the treating investigator.
Arm 1: Confirmed Histological Diagnosis of Sarcoma Intratumoral Administration of AdAPT-001 (1.0 x 10¹² viral particles) on Day 1 and 15 of each 28-day cycle for up to 12 injections with or without a checkpoint inhibitor.
Arm 2: Confirmed Histological Diagnosis of Advanced Solid Tumor indicated to receive at least one checkpoint inhibitor.
.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jeannie Williams
- Phone Number: 858-947-6644
- Email: jwilliams@epicentrx.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Active, not recruiting
- City of Hope
-
San Marcos, California, United States, 92069
- Recruiting
- California Cancer Associates for Research and Excellence, cCARE
-
Contact:
- Alberto Bessudo, MD
- Phone Number: 760-747-8935
-
Principal Investigator:
- Alberto Bessudo, MD
-
Santa Monica, California, United States, 90404
- Active, not recruiting
- Providence Saint John's Health Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Principal Investigator:
- Brian Gastman, MD
-
Contact:
- Brielle Eble
- Phone Number: 866-223-8100
-
-
Texas
-
Dallas, Texas, United States, 75230
- Recruiting
- Mary Crowley Cancer Research
-
Principal Investigator:
- Minal Barve, MD
-
Contact:
- Minal Barve, MD
- Phone Number: 972-566-3000
- Email: referral@marycrowley.org
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Anthony P Conley, MD
-
Principal Investigator:
- Anthony P Conley, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is capable of understanding the purpose and risks of the study and has provided written Informed Consent.
- Subject is male or female, aged at least 18 years.
- Subject has a histologically or cytologically confirmed diagnosis of an advanced malignant solid tumor(s) who have received all conventional therapies considered appropriate by Investigator and have a tumor that is easily accessible and/or palpable for treatment. Ultrasound guidance may be used to aid administration.
- Subject's Eastern Cooperative Group (ECOG) performance status is 0-1 at Screening.
Subject has acceptable liver function at Screening, as evidenced by:
- Bilirubin < 1.5 x ULN (upper limit of normal)
- AST (SGOT) and ALT (SGPT) < 3.0 x ULN (upper limit of normal)
- Alkaline Phosphatase < 2.5 x ULN (upper limit of normal)
- Subject has a Serum Creatinine < 1.5 x ULN (upper limit of normal)
Subject has acceptable hematologic status at Screening, as evidenced by:
- Absolute neutrophil count > 1,500 cells/mm3; > 1.5 x 109/L, and
- Platelet count > 75,000/mm3; > 75.0 x 109/L, and
- Hemoglobin (HGB) ≥ 8.0 g/dL; ≥ 5.6 mmol/L
- Subject has an INR < 1.5
- Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least one year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of AdAPT-001. Medically acceptable contraception is defined as either: 1) usage by at least one of the partners of a barrier method of contraception, together with usage by the female partner, commencing at least three months prior to Study Day 1, of a stable regimen of any form of hormonal contraception or an intra-uterine device, or 2) usage by the couple of a double-barrier method of contraception. Use of a single-barrier method alone or abstinence alone is not considered adequate.
- Subject is willing and able to comply with all protocol procedures, evaluations and rescue measures.
- OPTIONAL: Archival formalin-fixed paraffin-embedded block(s) or previously cut archival tissue for at least 5 unstained slides (if available).
Exclusion Criteria:
- Presence of a serious co-morbid medical condition, or a clinically significant laboratory finding(s) that, in the opinion of the Investigator, suggests the presence of an infectious, endocrine, and/or other inadequately treated systemic disorder.
- A known uncontrolled active bacterial, fungal, or viral infection. No subject with an active SARS-CoV-2 infection (within 14 days of a positive test)
- Known positive history of human immunodeficiency virus (HIV) test
- Subjects who have active hepatitis.
- If female, subject is pregnant and/or breastfeeding.
Subjects with active autoimmune disease or history of autoimmune disease that might recur and may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded.
Note: Subjects in any condition requiring systemic treatment with corticosteroids (prednisone > 10 mg/day or equivalent of the similar drug) or other immunosuppressive agents within 14 days before AdAPT-001), but currently or previously treated with any of the following steroid regimens were included: Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption; prophylactic short-term use of corticosteroids.
- Prior adenoviral therapy for any indication except vaccination against infectious disease. Subjects receiving COVID-19 or live vaccination, cannot start treatment until 7 days after completing the vaccination. Recommend waiting at least 28 days from AdAPT-001 dose prior to receiving COVID-19 vaccination. Concurrent treatment with Evusheld is allowed.
- Chemotherapy or immunotherapy within 14 days of study treatment. Hormonal therapy (including tamoxifen, aromatase inhibitors, and gonadotropin releasing hormone agonists) is allowed. Concurrent treatment with bisphosphonate and RANK ligand inhibitor is allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PART 3: Expansion
Up to 45 subjects will be enrolled in the expansion cohort to receive either AdAPT-001 on Days 1 and 15 of 28-day cycles or AdAPT-001 on Days 1 and 15 plus a checkpoint inhibitor of 28-day cycles.
|
Oncolytic virus administered by intratumoral injection
Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
|
Experimental: PART 1: Dose Escalation Safety Run-In (Enrollment Completed)
Subjects will be treated with AdAPT-001 as a single injection, one time.
|
Oncolytic virus administered by intratumoral injection
|
Experimental: PART 2: Dose Expansion Single-Agent (Enrollment Completed)
6 subjects will be enrolled in the Lead In Cohort.
A Safety Analysis will be performed after 6 subjects have received at least 24 doses.
Upon Safety team review as a continuous reassessment of safety, an additional 19 subjects may be enrolled.
All subjects in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.
|
Oncolytic virus administered by intratumoral injection
|
Experimental: Phase 2
Approximately 55 to 80 subjects with advanced solid tumors including sarcoma to receive either AdAPT-001 on Days 1 and 15 of 28-day cycles or AdAPT-001 on Days 1 and 15 plus a checkpoint inhibitor of 28-day cycles..
|
Oncolytic virus administered by intratumoral injection
Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of a multiple dose regimen of AdAPT-001
Time Frame: 6 months
|
The safety data will include adverse events, serious adverse events, performance status, clinical laboratory tests, vital signs and physical examination results.
|
6 months
|
Dose Limiting Toxicities (DLT)
Time Frame: 28 days
|
All subjects in PART 1 will be assessed for the development of dose-limiting toxicity (DLT) during treatment with AdAPT-001.
The DLT assessment period is defined as: Day of Injection through 28 days post injection (Safety Follow Up).
A DLT will be defined as any Grade 3 or higher adverse event, as assessed by the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.
|
28 days
|
Maximum tolerated dose
Time Frame: 28 days
|
In PART 1, A MTD is determined if any cohort experiences 2 subjects with DLT's.
|
28 days
|
Anti-tumor activity of the two-arm dose regimens of AdAPT-001 in Phase 2
Time Frame: 6 months
|
To evaluate the efficacy of the two-arm dose regimens of AdAPT-001 in subjects with advanced solid tumors that have progressed after treatment with standard therapies or for which there are no appropriate therapies available as measured by durable (≥4 months) stable disease per Response Evaluation Criteria in Solid Tumors (RECIST).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-tumor activity of AdAPT-001
Time Frame: 6 months
|
In PART 2 and PART 3, overall response rate (ORR) and best overall response rates per response evaluation criteria outlined in Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1), as well as progression-free survival (PFS), and duration of response will be assessed.
|
6 months
|
Objective response rate
Time Frame: 6 months
|
Preliminarily to assess anti-tumor activity of AdAPT-001 by objective response rates (ORR) and best overall response rates per response evaluation criteria outlined in RECIST guideline (Version 1.1),
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-tumor activity by iRECIST
Time Frame: 6 months
|
ORR and best overall response rates per Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
|
6 months
|
Biodistribution
Time Frame: 6 months
|
This outcome will measure TGFβ trap concentrations in the serum and, in patients who consent to tissue collections, test for TGFβ trap expression in the treated tumors.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bryan Oronsky, MD PhD, EpicentRx, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BETA-PRIME
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
David DickensWithdrawnSoft Tissue Sarcoma | Bone Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Metastatic Bone Sarcoma | Unresectable Bone SarcomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
Clinical Trials on AdAPT-001
-
Boston UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPrediabetesUnited States
-
University of MinnesotaArizona State UniversityCompleted
-
University of MinnesotaCompletedParentingUnited States
-
University of California, IrvineNational Institute of Mental Health (NIMH); Northwestern University; Mental Health...CompletedDepression, AnxietyUnited States
-
Kaiser PermanenteWithdrawnDepression | AnxietyUnited States
-
East Carolina UniversityAkron Children's Hospital; Palliative Care Research Cooperative GroupCompleted
-
Michigan State UniversityNational Center for Complementary and Integrative Health (NCCIH); Spectrum...Active, not recruitingAnxiety | Functional Abdominal Pain SyndromeUnited States
-
University of MinnesotaCompleted
-
University of California, Los AngelesCenter for Adoption Support and EducationUnknownPrevent Disorders in Children Adopted From Foster CareUnited States
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); Duke University; RTI InternationalNot yet recruitingObesity | Overweight | Overweight and ObesityUnited States